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ABSTRACT 
   Diabetes mellitus is a common metabolic disease. Its association with low level of testosterone is 
controversial. This study aimed to investigate the association between serum total testosterone, free 
testosterone index (FTI), and sex hormone-binding globulin (SHBG) in Iranian men with type 2 diabetic. 
A case-control study was conducted on 38 non-diabetic and 36 diabetic men aged 40-60 years old with 
Body Mass Index (BMI) 18-40 (kg/m2). Fasting serum total testosterone, SHBG, FBS (Fasting Blood 
Sugar), HbA1C, and other hormone tests were measured. Logistic regression adjusted models was used 
to asses the association of total testosterone, free testosterone and SHBG level with type 2 diabetes. 
The mean age of participants was 47.7±5.7 years. Serum total testosterone, FTI, and SHBG had no 
difference between case and control groups. There was no significant difference in total testosterone, FTI 
and SHBG between the patient with and without glycemic control. 
Logistic regression analysis showed an inverse relationship for total testosterone in the lower tertile 
concentration and type 2 diabetes, but adjustment of HbA1c eliminated the correlation between total 
testosterone and diabetes. According to logistic regression analysis, SHBG and FTI were not 
significantly associated with type 2 diabetes. 
Our findings suggest that serum testosterone level of the type 2 diabetics may not be lower than healthy 
subjects in Iranian men. 
 





   Diabetes Mellitus (DM) is a major cause of 
renal failure, lower limb amputation for non-
traumatic cause, and blindness in adults and 
with its rate appears to be increasing through the 
world becoming the most frequent cause of 
death[1].  
Since 1960s the research has shown that the 
testosterone level in type 2 diabetic patients is 
lower than non-diabetic men. The same is true 
for the free testosterone level [2-4]. However, 
some other studies did not report such a 
correlation [5-6].  
Lack of testosterone can cause a decrease in 
libido, impotency, decrease in muscle mass,  
 
 
fatigue, decrease in bone density and 
osteoporosis. Because the diabetes is a common 
disease and considering the importance and the 
role of testosterone it would be worthful to 
investigate the factors that can cause a decrease 
in testosterone level in diabetic patients. 
Considering the conflicting results on the 
correlation between serum testosterone level 
and diabetes and based on the fact that only a 
few case-control studies, especially in Iran, had 
been undertaken, we decided to investigate the 
relationship between level of testosterone 
hormone and type 2 diabetes in Iranian men.  
 




MATERIALS AND METHODS 
   Current study was a case-control study. In this 
study 74 men aged 47.7±5.7 years, including 38 
diabetic patients admitted into department of 
endocrinology at Firouzgar hospital (case) and 
36 male non diabetic participants working in the 
department of endocrinology at Firouzgar 
Hospital (control) were randomly assessed. All 
the participants were privately interviewed 
during a face to face interview by one trained 
personnel. After receiving necessary 
information on the aimers of participating in the 
study, all patients signed a written informed 
consent form and then answered some questions 
regarding the history of a certain underlying 
diseases, medication use, and smoking habits. 
Inclusion criteria were aged 40-60 years and 
BMI between 18-40 kg/m
2
.  All the participants 
with a hypophyseal disease, renal failure, or 
thyroid disorders were excluded from the study. 
The participants were then weighed with indoor 
clothing without shoes. Weight was measured to 
the nearest 100 grams using a digital personal 
scale. Height was measured using a tape meter, 
to the nearest centimeter, in standing position 
without shoes. Body mass index (BMI) was 
calculated by taking a person's weight (Kg) 
dividing by their height (meter) squared. All the 
male participants with a BMI between 18 and 
40 having other inclusion criteria were included 
in the study. 
After 8-10 hours fasting, blood samples were 
taken between 7 to 9 a.m. and serum total 
testosterone, SHBG, LH, FSH, FBS, HbA1C 
were measured. To increase the accuracy of the 
test, all the tests were performed by the same 
personnel at the department of endocrinology at 
Firouzgar Hospital. Fasting blood sugar (FBS) 
of sampling day was determined by the 
enzymatic colorimetric method with glucose 
oxidase. 
HbA1C was determined by ion exchange 




method was used to measure FSH, LH 
hormones. Serum total testosterone was 
measured using RIA immunoassay and SHBG 
was measured using ELIZA method. FTI was 
calculated by (total testosterone, in nmol/L) × 
100 divided by (SHBG, in nmol/l)[7].  
Occasional or daily smoking was defined 
against non-smoking. The number of cigarettes 
per day multiply by the number of smoking 
years was expressed as pack/year. BMI≤ 25 (kg 
per square meter) was defined against BMI 
above 25. Based on American Diabetes 
Association glycemic control was defined when 
HbA1C<7 percent was achieved.  
Data distribution was analyzed using 
Kolmogorov-smirnov test. For variables with a 
normal distribution (parametric variables) 
including age, BMI, HbA1C, serum total 
testosterone, and LH, independent sample T test 
was used. For non-parametric variables that did 
not have a normal distribution Mann- Whitney 
test was used. To asses the association of 
testosterone level with type 2 diabetes, 
concentration of total testosterone, free 
testosterone and SHBG were dichotomized by 
the lower tertile and entered into logistic 
regression models adjusting for 1) age; 2) age 
and smoking (pack/year); 3) variables in model 
2 and BMI (overweight and non overweight); 4) 
variables in model 3 and HbA1c (control 
glycemic and non control glycemic) 
The statistical significance level set at 0.05. All 
the statistical analyses were performed using 
SPSS (version 15) software.  
 
RESULTS 
   The samples of this study were 74 men 
between 40 and 60 years (47.7±5.7) including 
36 diabetic and 38 non-diabetic men. As shown 
in table 1, mean age and BMI did not show any 
significant difference between diabetic and non-





















95%CI P value 
Age(year) 47.6±5.5* 47.5±5.9 -2.5 , 2.77 0.92 
BMI(kg/m
2) 27.2±3.4 28.0±4.1 -2.6 , 2.77 0.33 
Smoking(pack/year) 3.42±8.5 3.06±6.2  0.75 
FBS(mg/dl) 92.0±11.1 138.9±40.8  0.0001
†
 
HbA1c 4.92±0.61 7.14±0.69 -2.52 , -1.91 0.0001
†
 
Total Testosterone(ng/ml) 4.14±1.3 4.66±1.4 -1.13 , -0.08 0.09 
Free Testosterone Index –FTI 102±38.6 115±64.7  0.82 
Sex Hormone Globulin -SHBG(nmol/l) 15.3±6 17.8±9.7  0.69 
LH 4.40±2.3 4.87±2.1 -1.50 , 0.54 0.35 
FSH  6.17±3.0 4.37±1.7   0.02
†
 
TSH 2.32±1.3 2.412.3  0.04
†
 
Prolactin  6.96±2.8 7.86±3.4  0.17 
 
Independed t-test was used for parametric variables (age, BMI, HbA1C, total testosterone, LH) and Man-Whitney was used for 
non parametric variables. 
 *Mean±SD                 
 †Significant difference (p<0.05) 
 
Also, based on HbA1C, diabetic samples were 
subdivided into two groups of good glycemic 
control (n=18) and poor glycemic control 
(n=18) (Figure 1). There was no significant 
difference in total testosterone and free 
testosterone index between the patient with and 
without glycemic control. Although poor 
glycemic control diabetic samples had lower 
SHBG in comparison to another group; the 
difference was not statistically significant 
(P=0.07). 
Logistic regression analysis showed an inverse 
relationship for total testosterone in the lower 
tertile concentration and type 2 diabetes, but 
adjustment of HbA1c eliminated the correlation 
between total testosterone and diabetes (Table 
2)






























































Figure 1: Plasma concentration of free testosterone index, SHBG and total testosterone in good glycemic control and poor 
glycemic control diabetics 
Glycemic control Nonglycemic control 
Glycemic control Nonglycemic control 
Glycemic control Nonglycemic control 




Table 2: ORs for type 2 diabetes for Iranian men in the lowest third of concentrations of serum total and calculated free 
testosterone and SHBG  
 
 Lowest third of total 
testosterone 
Lowest third of calculated 
free testosterone 
Lowest third of SHBG 






 2.00(0.69-5.76) 1.75(0.66-4.67) 
Model 3 0.15(0.04-0.54)
 *
 1.80(0.62-5.24) 1.45(0.49-4.27) 
Model 4 0.27(0.06-1.10) 2.27(0.51-10.02) 2.26(0.61-8.27) 
 
Data are ORs (95% CI). Model 1: age-adjusted. Model 2: adjusted for age and smoking (pack/year). Model 3: adjusted for the 
variables in model 2 and BMI (overweight and non overweight). Model 4: adjusted for the variables in model 3 and HbA1c 
(control glycemic and non control glycemic) 
 
DISCUSSION
   Mean BMI and age did not show a significant 
difference between diabetic and non-diabetic 
group. Mean FBS and HbA1C was significantly 
higher in diabetic patients in comparison to non-
diabetic participants.  
No difference was observed in LH between the 
two groups, However, FSH level in diabetic 
group was significantly lower than non-diabetic 
group. We could not find a clinical reason for 
this difference. TSH was significantly higher in 
the diabetic group than non-diabetic one. Since 
no simultaneous measurement of T4 and free T3 
was performed and only one TSH test, without 
the possibility of repetition, was performed, it 
might not be possible to make a correct 
judgment. 
Like other studies, our study showed that no 
significant relationship exist between the good 
glycemic control (based on HbA1C≤7) and 
serum testosterone level [2, 8-9]. In A study in 
2009 on the effect of glycemic control 
(HbA1C≤7) on leydig cell function included 30 
men with T2DM with the mean age of 57 and 
mean BMI of 28 without overt hypogonadism 
and 30 people as the control group with the 
same age and BMI. To study leydig cell 
function  ̧FTI, SHBG, LH, insulin-like factor 3 
(INSL3) were measured. The results of the 
study showed that FTI and INSL3 levels were 
lower in the diabetic group in comparison to the 
control group. The study also showed that 
hormonal parameters did not differ between 
patients with poor or good glycemic control [3]. 
Like our study, these studies confirm the point 
that there is no significant relationship between 
HbA1C and serum total testosterone, FTI and 
SHBG hyperglycemia is not the reason for the 
lower testosterone in diabetic patients. 
However, in a study on 159 diabetic patients 
with erectile dysfunction (ED), EI-Sakka in 
September of 2009 showed that after 3-6 
months glycemic control (based on FBS) with 
insulin, hypoglycemic drugs or changes in the 
life style, the serum insulin decreased and serum 
total testosterone increased. Although they only 
measured FBS to study the glycemic control 
(and did not measure HbA1C), unlike our study 
and some similar studies, they reported a direct 
correlation between FBS and total 
testosterone[9]. 
In the present study, no significant difference 
was found between total testosterone level, free 
testosterone index and SHBG in diabetic and 
non-diabetic subjects. In the longitudinal study 
undertaken in Iran on 836 healthy adult men 
(20-80 years), no correlation was found between 
type 2 diabetes and total testosterone level, free 
testosterone index or SHBG [6]. This result was 
not in agreement with the study conducted in 
Boston that mentioned in white Caucasian race, 
the changes of sexual hormones in patients with 
metabolic syndrome was more than other 
races[10].One reason may be due to racial 
different and the other may be different patterns 
of socio-economic status [11]. It seems that 
Iranian diabetics have not serum testosterone 
level lower than healthy subjects; however our 
findings suggest further studies on this issue.   
Limitations of this study were small sample 
size, the lack of repeat experiments in other 
laboratory and lack of direct measurement of 
free testosterone. However, measurement of FTI 
certainly did not decrease the accuracy of the 
study. 
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